Meet the Immuneering Corporation team at the 2024 Morgan Stanley Annual Global Health Conference! Co-Founder and Chief Executive Officer Ben Zeskind, Ph.D., will participate in a fireside chat on September 6 at 10am ET to discuss our universal-RAS program for advanced solid tumors harboring #RASmutations. We will also be arranging 1x1 investor meetings for those interested in learning more. For more details, see our press release: https://buff.ly/3z9hV1L
Immuneering Corporation
Biotechnology
Cambridge, MA 2,580 followers
Better Medicines Through Signaling Dynamics
About us
Immuneering is a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying its deep knowledge of translational bioinformatics to every stage of the drug development process. Immuneering has more than a decade of experience in translational bioinformatics and generating insights into drug mechanisms of action and patient treatment responses. Building on this experience, Immuneering has developed a disease-agnostic platform that enables the company to utilize human data, novel biology and chemistry, and translational planning to create and advance its wholly owned pipeline. Immuneering’s current development programs in oncology are focused on providing potential treatments for patients with solid tumors caused by mutations of oncologic signaling pathways, including the MAPK pathway. Immuneering’s lead product candidate, IMM-1-104, is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. Additionally, Immuneering has six other oncology programs in the discovery stage that are designed to target either the MAPK or mTOR pathway, and two neuroscience programs in the discovery stage. For more information, please visit www.immuneering.com.
- Website
-
http://www.immuneering.com
External link for Immuneering Corporation
- Industry
- Biotechnology
- Company size
- 11-50 employees
- Headquarters
- Cambridge, MA
- Type
- Privately Held
- Founded
- 2008
- Specialties
- Computational Biology, Genomics, Drug Developement, Neurodegenerative Disease, and Oncology
Locations
-
Primary
Get directions
245 Main Street
Second Floor
Cambridge, MA 02142, US
-
Get directions
667 Madison Avenue
5th Floor
New York, NY 10065, US
-
Get directions
9620 Towne Centre Dr
#100
San Diego, CA 92121, US
Employees at Immuneering Corporation
Updates
-
According to the American Lung Association, about 20-25% of lung cancer patients have some kind of #KRAS mutation. We’re honored to be advancing important research to support this underserved group of patients. Immuneering is conducting a Phase 1/2 trial for people with advanced RAS-mutated solid tumors, including NSCLC: https://buff.ly/3XfebFU #LungCancer #RASMutations #UniversalRAS #MAPKPathway #SolidTumors #DrugDiscovery #CancerResearch
-
-
Enjoy these last few weeks of summer but please remember to protect your skin! According to the American Academy of Dermatology, excess exposure to UV radiation from sunlight increases the risk of all skin cancer types including melanoma, a deadly form of skin cancer. Our IMM-1-104 Phase 1/2 clinical trial is enrolling people with advanced solid tumors, including NRAS-mutant #melanoma, one of the most common and aggressive forms #melanoma. Learn more: https://buff.ly/3hL4Z5r #RASMutations #SkinCancer #UniversalRAS #MAPKPathway #SolidTumors #DrugDiscovery #CancerResearch #TargetedOncology #MetastaticCancer #AdvancedCancer
-
-
Today we announced our second quarter 2024 financial results and recent corporate highlights. See our press release for details: https://buff.ly/3LV3iSz #RASMutations #UniversalRAS #MAPKPathway #SolidTumors #DrugDiscovery #CancerResearch #TargetedOncology #MetastaticCancer #AdvancedCancer
-
-
We are honored to join Lung Cancer Foundation of America in recognition of #WorldLungCancerDay on Thurs Aug 1 to highlight the need for more #LungCancer research. Learn more: https://buff.ly/3WrPmEE #NSCLC #DrugDiscovery #CancerResearch #WLCD2024
-
-
Today we announced that IMM-1-104 has been granted Fast Track designation for the treatment of first-line pancreatic ductal adenocarcinoma (PDAC); providing the potential to accelerate IMM-1-104’s path to U.S. FDA submission for PDAC. Learn more here: https://buff.ly/3Wrsox9 #PancreaticCancer #CancerResearch
-
-
DYK? #NRAS mutant melanoma is one of the most common and aggressive forms of melanoma, comprising ~20% of total cases. Our IMM-1-104 clinical trial is enrolling people with advanced solid tumors harboring RAS mutations, such as NRAS-mutant #melanoma. https://buff.ly/3hL4Z5r
-
-
Our CSO Brett Hall, PhD, and CBO E.B. Brakewood were in San Diego at #BIO2024 last month to meet with #biotech and #pharma leaders and provide an update on our pipeline of universal-RAS/RAF medicines. Biotechnology Innovation Organization
-
-
We are delighted to host students from local high schools to the Immuneering Summer Internship program. These interns are supporting our researchers, with the opportunity to play a role in helping to develop universal-RAS/RAF medicines with broad activity for large populations of cancer patients. Join us in welcoming our newest Immuneers! #RASMutations #UniversalRAS #MAPKPathway #SolidTumors #DrugDiscovery #CancerResearch #TargetedOncology
-